Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Clin Genet. 2019 Nov 24;97(2):370–375. doi: 10.1111/cge.13654

Table 1.

Patient sociodemographic characteristics, disease/treatment characteristics, family history, and provider characteristics, and survival data for participants (N=557).

Mean (SD) Range N (%)
Patient Sociodemographic Characteristics
Current Age (years) 61.6 (11.4) 27–88
Race: % White 523 (94%)
Marital Status: % Married/Cohabitating 375 (67%)
Education
 ≤HS/HS grad/vocational school 182 (33%)
 Some college/college grad 232 (42%)
 Professional school 66 (12%)
 Unknown 77 (14%)
Children: % yes 448 (80%)
Insurance Type
 Private 270 (48%)
 Non-private (Medicare, Medicaid, self-pay, medically needy) 287 (52%)
Disease/Treatment Characteristics
Year of diagnosis
 2001–2013 501 (90%)
 2014–2015 56 (10%)
Primary cancer site: % ovarian 494 (89%)
Grade: % high 542 (97%)
Stage
 III 432 (78%)
 IV 125 (22%)
Histotype: % serous 482 (87%)
Debulking status: % optimal 462 (83%)
Platinum sensitivity: % yes 384 (69%)
Clinical trial enrollment: % yes 159 (29%)
Number of therapy lines 3.4 (2.7) 0–17
Family History of Cancer
History of breast cancer: % yes 119 (21%)
History of ovarian cancer: % yes 39 (7%)
Provider Characteristics
Gender of gynecologic oncologist
 Male 458 (82%)
 Female 99 (18%)
Type of chemotherapy provider
 Gynecologic oncologist 368 (66%)
 Medical oncologist 189 (33%)
Survival Data
Progression-free survival (months) 18.1 (24.4) 0–172
Overall survival (months) 47.1 (34.2) 0–194